ALK and non-small cell lung carcinoma: In this cost-effectiveness analysis, we comprehensively compared the effectiveness and cost of domestic ALK-TKI ensartinib with five imported ALK-TKIs in the first-line treatment of Chinese patients with advanced ALK-positive NSCLC.